Variant Bio Expands Target Discovery Collaboration With Boehringer Ingelheim Into Cardiovascular Disease
Sept 23 (Reuters) -
VARIANT BIO EXPANDS TARGET DISCOVERY COLLABORATION WITH BOEHRINGER INGELHEIM INTO CARDIOVASCULAR DISEASE
VARIANT BIO: ELIGIBLE FOR ADDITIONAL UPFRONT, PLATFORM ACCESS AND MILESTONE PAYMENTS FOR A TOTAL DEAL VALUE POTENTIALLY EXCEEDING $250 MILLION
Further company coverage: [ ]